Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Pharmaceutical Market: Israel
Management Report
Published: January 2010
Pages: 32
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Israel borders Lebanon, Syria, Jordan, Egypt and the Mediterranean Sea. Lying within its borders are areas that the Palestinians claim as their own; the threat of terrorism dominates the political landscape. Israel’s healthcare sector remains one of the strongest in the Middle East and the growing elderly population has forced the ruling administrations, partly due to political pressure and strategy, to expand drugs and medical treatments available under the “health basket”, although these items are by no means constant, and have been known to change from time to time.
Israel represents the largest pharmaceutical market in the Middle East, with per capita spending rates just outside the world’s top 20. The country has an advanced healthcare system and healthcare spending is high; around 8.0% of total GDP is spent on healthcare, and per capita spending rates are considered high by regional and world standards. Much of spending is in the public sector and the government has made allowances in recent years to expand the number of drugs and treatments offered by public health insurance programmes. The country also has a rapidly growing elderly demographic that is contributing to rising healthcare costs.
Much of the Israeli pharmaceutical market is controlled by the four general sick funds - Kupat Holim Clalit, Macabee, Meuhedet and Leummit - which account for over 90% of drug expenditure while the Ministry of Health and the Ministry of Defence and the private sector are responsible for remaining expenditure.
Pharmaceutical giant Teva continues to flourish in Israel. In 2008, the company achieved record sales of US$11,085 million, a rise of 17.8% over the US$9,408 million achieved in 2007. Operating income for 2008 was US$1,145 million, less than half the US$2,395 million achieved in 2007. The majority of sales were achieved abroad, with only 30% from within Israel.
The market for generics remains strong, with Teva dominating, but facing increased competition from other local manufacturers and imported drugs. In addition, the country continues to enhance its burgeoning reputation in the field of biotechnology, and possesses first class research and development facilities.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and
Israel represents the largest pharmaceutical market in the Middle East, with per capita spending rates just outside the world’s top 20. The country has an advanced healthcare system and healthcare spending is high; around 8.0% of total GDP is spent on healthcare, and per capita spending rates are considered high by regional and world standards. Much of spending is in the public sector and the government has made allowances in recent years to expand the number of drugs and treatments offered by public health insurance programmes. The country also has a rapidly growing elderly demographic that is contributing to rising healthcare costs.
Much of the Israeli pharmaceutical market is controlled by the four general sick funds - Kupat Holim Clalit, Macabee, Meuhedet and Leummit - which account for over 90% of drug expenditure while the Ministry of Health and the Ministry of Defence and the private sector are responsible for remaining expenditure.
Pharmaceutical giant Teva continues to flourish in Israel. In 2008, the company achieved record sales of US$11,085 million, a rise of 17.8% over the US$9,408 million achieved in 2007. Operating income for 2008 was US$1,145 million, less than half the US$2,395 million achieved in 2007. The majority of sales were achieved abroad, with only 30% from within Israel.
The market for generics remains strong, with Teva dominating, but facing increased competition from other local manufacturers and imported drugs. In addition, the country continues to enhance its burgeoning reputation in the field of biotechnology, and possesses first class research and development facilities.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and